Alzheimer's groups protest CMS decision on Biogen's Aduhelm
Toa55/iStock via Getty Images


Groups supporting Alzheimer's patients are putting pressure on the Centers for Medicare and Medicaid Services ("CMS") to reverse a preliminary decision that severely limits coverage of Biogen's (BIIB
+0.0%) Alzheimer's drug Aduhelm (aducanumab).
CMS earlier this month announced it would limit coverage of the treatment to those already enrolled in clinical trials.

Alzheimer's Association Chief Executive Harry Johns told Reuters that the CMS decision "usurps FDA's role in drug approvals" and is "an unprecedented and terrible draft decision."
"Congress has to know how bad this will be for patients," added John Dwyer, president of Global Alzheimer's Platform Foundation.
CMS will make a final coverage determination in April.
Biogen has also said it will turn up the heat on CMS with a flurry of public comments.
Dear Readers: We recognize that politics often intersects with the financial news of the day, so we invite you to click here to join the separate political discussion.